Streetbeat News

Stock Prices

BLUE

Trading in shares of Bluebird Bio, Inc (BLUE) has resumed after being temporarily halted.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 6:46 pm

DPZ

UBER

Morgan Stanley analyst Brian Harbour has reiterated an Overweight rating on Domino's Pizza Inc (DPZ) and increased the price target from $435 to $455, citing a strong long-term outlook. The analyst highlighted DPZ's strategic details, financial goals, and positive near-term indicators from its first investor day in years. DPZ is expected to continue gaining market share and aims for over $3 billion in incremental sales over the next 5 years. The partnership with Uber Technologies Inc (UBER) is also seen as a positive contributor to sales. DPZ's new long-term algorithm through 2028 includes a 7%+ global retail sales growth, 3%+ same-store sales growth, and 1,100+ annual net unit growth. The company targets $400 million incremental operating income by 2028, driven by top-line growth, disciplined investments, and moderate margin expansion post-2024. Internationally, DPZ aims for over $4 billion incremental sales through FY28, with significant growth expected from China and India. Technological advancements, including automation and AI, are seen as potential boosts for customer and store operations. Despite the positive outlook, DPZ shares were trading down by 1.94% at $394.22.

Portfolio Pulse from Shivani Kumaresan

December 08, 2023 | 6:45 pm

DOCU

DocuSign, Inc. (NASDAQ:DOCU) reported Q3 revenue of $700.42 million, surpassing the consensus estimate of $690.13 million, and earnings of 79 cents per share, beating estimates of 63 cents per share. The company saw a 1.7% beat on subscription revenue, record free cash flow of $240 million, but expects net dollar retention (NDR) to fall below 100% in Q4, indicating down-sell pressure. Despite better than expected billings growth and enterprise additions, the macro environment limits expansion, leading to a Hold rating from Needham analyst Scott Berg. DOCU shares rose 5.63% to $50.11.

Portfolio Pulse from Anusuya Lahiri

December 08, 2023 | 6:42 pm

BLUE

Shares of Bluebird Bio were halted on a circuit breaker due to a sharp decline, with the stock plummeting 34.5%.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 6:42 pm

BLUE

Trading in shares of Bluebird Bio (BLUE) has resumed after being temporarily halted.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 6:40 pm

BLUE

CRSP

VRTX

The FDA has approved two gene-editing cell therapies for sickle cell disease, Casgevy and Lyfgenia, for patients 12 years and older. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR/Cas9 technology and has also been conditionally approved in the U.K. for sickle cell disease and beta-thalassemia. Bluebird Bio's Lyfgenia uses a lentiviral vector for genetic modification and has received FDA approval ahead of its PDUFA date. However, shares of CRISPR Therapeutics, Vertex Pharmaceuticals, and Bluebird Bio fell after the announcement.

Portfolio Pulse from Vandana Singh

December 08, 2023 | 6:35 pm

BLUE

Shares of Bluebird Bio were halted on a circuit breaker due to a rapid decline, with the stock plummeting by 20.4%.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 6:31 pm

DECK

Deckers Outdoor (NYSE:DECK) has significantly outperformed the market, with an average annual return of 40.41% over the past 5 years. An initial investment of $1000 in DECK stock would now be worth $5,570.58. The company's market capitalization stands at $17.87 billion.

Portfolio Pulse from Benzinga Insights

December 08, 2023 | 6:30 pm

SMCI

Super Micro Computer (NASDAQ:SMCI) has significantly outperformed the market, with an average annual return of 74.53% over the past 5 years. A $100 investment in SMCI 5 years ago would be worth $1,634.25 today. The company's market capitalization stands at $14.24 billion.

Portfolio Pulse from Benzinga Insights

December 08, 2023 | 6:30 pm

BLUE

Trading in shares of Bluebird Bio (BLUE) has resumed after being temporarily halted.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 6:30 pm